CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity;
CTA to be filed in 2H 2025
MONTREAL, Sept. 4, 2025 / — Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin (A1AT) deficiency, announced today the closing of a US $32 million financing round.
The round included participation from all existing investors including: Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital’s Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria.
“This financing enables us to generate the first clinical proof of concept data with our corrector for MC4R-d driven obesity, a serious and debilitating condition without current treatment options,” commented Dr. Clarissa Desjardins, CEO of Congruence. “We will also advance our programs in GBA-1 Parkinson’s Disease and Alpha-1 Antitrypsin Deficiency toward Development Candidate nomination this year.”
Congruence plans to start a Phase 1 trial of CGX-926 in healthy volunteers, including a Phase 1b efficacy cohort in MC4R-d patients, in early 2026. Congruence will also advance its programs targeting Parkinson’s Disease and A1AT-deficiency into late preclinical testing.
“Congruence is building a transformative pipeline of drugs it has discovered leveraging its powerful computational engine, Revenir™. The team has demonstrated scientific rigor and capital efficiency in advancing these important medicines into late preclinical testing,” commented Daniel Hétu, M.D., MBA, Managing Director at Lumira Ventures. “We are proud to continue to support Congruence as it advances its lead program CGX-926 into clinical testing and inches closer towards its mission of treating diseases of high unmet medical need.”
The Company also continues to advance its R&D collaborations, including a multi-target deal in oncology with Ono Pharmaceuticals and another collaboration on a difficult to drug metabolic target with an undisclosed pharmaceutical company.
“Too many patients with devastating genetic conditions have been left without effective treatments. Congruence’s small-molecule corrector approach offers new hope for people affected by MC4R-driven obesity, GBA Parkinson’s, A1AT deficiency and cancer. We are honored to support their mission through our investment in Congruence,” added Nancy Harrison, Venture Partner at Amplitude Ventures.
About Revenir™ Drug Discovery Platform
Revenir™, Congruence’s proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, Revenir™ predicts small molecule induced correction of the underlying pathogenic defect in proteins.
About Congruence Therapeutics
Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson’s Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases.
For more information, please visit www.congruencetx.com.
Company Contact
Charles Grubsztajn
Chief Operating Officer
cgrubsztajn@congruencetx.com
Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243